Skip to main content

Advertisement

Fig. 5 | Biomarker Research

Fig. 5

From: Development of a fully automated chemiluminescence immunoassay for urine monomeric laminin-γ2 as a promising diagnostic tool of non-muscle invasive bladder cancer

Fig. 5

Comparison of mono-Ln-γ2 and Ln-332 values in patients with benign urological diseases and HDs. Dot plots of creatinine-corrected urine Ln-γ2 (Ln-γ2/crn) and Ln-332 (Ln-332/crn) from 41 patients with benign urological diseases and 44 healthy donors. The distributions of urine Ln-332/crn were wider than the distributions of urine Ln-γ2/crn in patients with benign urological diseases and in the healthy donors. These results indicate that Ln-332 is secreted into the urine of patients with benign urological disease and healthy donors, which could lead to false-positive diagnoses

Back to article page